Nelson E. Polo-Taborda, Servicio de Cardiología, Sanatorio Finochietto, Universidad de Buenos Aires, Buenos Aires, Argentina
María V. Verteramo, Servicio de Cardiología, Sanatorio Finochietto, Universidad de Buenos Aires, Buenos Aires, Argentina
Fadi A. Nehme, Servicio de Ecografía Cardíaca y Vascular, Sanatorio Finochietto, Universidad de Buenos Aires, Buenos Aires, Argentina
Víctor Darú, Servicio de Ecografía Cardíaca y Vascular, Sanatorio Finochietto, Universidad de Buenos Aires, Buenos Aires, Argentina
Miguel A. González, Departamento de Investigación Clínica, Sanatorio Finochietto, Universidad de Buenos Aires, Buenos Aires, Argentina
Antiphospholipid syndrome (APS) is an autoimmune disorder that has an incidence of 5 cases per 100,000 people per year. The diagnosis is based on the presence of a clinical event and positive antibodies. The manifestations are systemic with a prevalence of 80% of cardiac valve involvement, with Libman-Sacks endocarditis, valve thickening and thrombosis being some of these forms, predominantly mitral and aortic mostly when is the secondary manifestation of entities such as systemic lupus erythematosus (SLE). Treatment consists of anticoagulation, and primary treatment of collagenopathy. It is presented the case of a woman with heart failure, severe aortic stenosis as the clinical debut of valvular involvement due to secondary APS in the context of SLE and Libman-Sacks endocarditis. The result of the positive antibodies confirmed a triple positive APS with aortic valve involvement and requirement for anticoagulation, being of secondary etiology as it met diagnostic criteria for SLE, presenting as Libman-Sacks endocarditis. Anticoagulation is the treatment of choice in most cases without surgical requirement, with the treatment of collagenopathy.
Keywords: Thrombosis. Antiphospholipid. Lupus. Aortic valve. Libman-Sacks.
